Qnasl (Beclomethasone Dipropionate) Patent Expiration, LOE Window & CMS Spending

Qnasl (Beclomethasone Dipropionate) by Teva Pharmaceuticals: FDA Orange Book LOE 2031-10-21, 2 AB generics, $7.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN202813 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-10-21
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$7.1M
2024 Medicare Part D Spend$4.5M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 21.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.